PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis

Authors
Category Systematic review
JournalJournal of Clinical Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 4364f402efe499e5776fa06a36d2c6ae12fa3a88
First added on: Feb 10, 2025